Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BNO 1095
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : FGK Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 18, 2024
Lead Product(s) : BNO 1095
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : FGK Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bronchipret
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Frank Behrens
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Bronchipret on Antiviral Immune Response in Patients With Mild COVID-19
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Bronchipret
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Frank Behrens
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silimarit
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Recipient : Frank Behrens
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 03, 2021
Lead Product(s) : Silimarit
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Recipient : Frank Behrens
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BNO 1030 Extract
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Undisclosed
Recipient : Ivano-Frankivsk National Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Imupret
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 03, 2020
Lead Product(s) : BNO 1030 Extract
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Undisclosed
Recipient : Ivano-Frankivsk National Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chaste Berry Extract
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : Struk Tetiana
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 04, 2020
Lead Product(s) : Chaste Berry Extract
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : Struk Tetiana
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BX-1
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Recipient : Charite University, Berlin, Germany
Deal Size : Inapplicable
Deal Type : Inapplicable
Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2020
Lead Product(s) : BX-1
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Recipient : Charite University, Berlin, Germany
Deal Size : Inapplicable
Deal Type : Inapplicable
BX-1 in Spasticity Due to Multiple Sclerosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 28, 2018
Lead Product(s) : Sinupret
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sinupret Extract Coated Tablets in Chronic Rhinosinusitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 21, 2016
Lead Product(s) : Sinupret
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Centaurium Erythraea
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 24, 2015
Lead Product(s) : Centaurium Erythraea
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bronchipret
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 27, 2013
Lead Product(s) : Bronchipret
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable